NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)

0 followers


NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System.

The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

Employees

11-50

Links


Org chart

Collapse
Eran Ovadya
Chief Financial Officer
Yoram Drucker
Co-founder, Board Member

Teams

This company has no teams yet


Offices

This company has no offices yet